Described herein are polypeptides, systems, and methods that relate to using domains that bind specifically to a biotinylamide to control receptor and cellular activity.

Described are MMP8 inactivating antigen binding proteins, such as antigen binding proteins comprising an amino acid sequence that comprises 4 framework regions and 3 complementary determining regions; further described is the use of such antigen binding proteins to treat inflammation, such as, but not limited to, systemic inflammatory response syndrome, sepsis, LPS induced inflammation, renal ischemia/reperfusion injury, ventilation induced lung injury, periodontal inflammation, rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, Lyme arthritis and osteoarthritis.

The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.

The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNFα and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.

The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl2, Angptl3, Angptl4, Angptl5, Angptl6, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences.

There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.

The present disclosure provides anti-CTLA-4 antibody polypeptides, polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Deinococcus radiodurans phytochrome (DrBphP) light form-binding antibodies are disclosed and their use in light induced dimerization systems.

Provided in the present invention is a method for constructing a multispecific antibody. The method comprises the steps of: (i) constructing a first polynucleotide and a second polynucleotide, respectively, wherein the first polynucleotide and the second polynucleotide respectively encode a first polypeptide containing a CL region and a second polypeptide containing a CH1 region, and a disulfide bond may be formed between the CL region of the first polypeptide and the CH1 region of the second polypeptide, such that the antibody has a heterodimeric form; and (ii) expressing the first polynucleotide and the second polynucleotide to obtain the first polypeptide and the second polypeptide, and dimerize the first polypeptide and the second polypeptide to form a multispecific antibody with a heterodimeric form. The antibody of the present invention can simultaneously bind to different targets and maintain the binding activity of the original antibody, which plays a role when the target is a membrane surface receptor or a target in a solution and has a biological activity against multiple targets.

The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.